Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/jw-cayman-therapeutics-co-ltd">JW Therapeutics</a> is a clinical-stage cell therapy company at the forefront of China's nascent but rapidly growing CAR-T market, with its lead product, Carteyva (relmacabtagene autoleucel), approved for multiple hematological cancer indications.</li>
 <li>The company is currently in a high-growth, high-burn phase, characterized by rising revenues from Carteyva sales, but persistent and significant net losses due to heavy investment in R&amp;D and commercialization.</li>
 <li>Future growth hinges on the successful commercial ramp-up of Carteyva, expansion into new indications, advancement of its broader pipeline including therapies for solid tumors, and navigating a highly competitive and regulated market.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
JW Therapeutics is a clinical-stage cell therapy company at the forefront of China's nascent but rapidly growing CAR-T market, with its lead product, Carteyva (relmacabtagene autoleucel), approved for multiple hematological cancer indications.
  The company is currently in a high-growth, high-burn phase, characterized by rising revenues from Carteyva sales, but persistent and significant net losses due to heavy investment in R&amp;D and commercialization.
  Future growth hinges on the successful commercial ramp-up of Carteyva, expansion into new indications, advancement of its broader pipeline including therapies for solid tumors, and navigating a highly competitive and regulated market.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: JW Therapeutics (2126 HK) - Aug 2026

Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Sichuan Kelun-Biotech announces Phase 3 trial success for ADC-Keytruda combination therapy in first-line lung cancer. ImmuneOnco received Phase 3 trial approval for IMM0306 lenalidomide combination for follicular lymphoma in China.</li>
<li>Otsuka received FDA accelerated approval of Voyxact for immunoglobulin A nephropathy. Eisai has completed FDA submission of Leqembi Iqlik subcutaneous autoinjector as a weekly starting dose for early Alzheimer’s disease.</li>
<li>Alteogen secures $15M milestone payment from Merck as Keytruda subcutaneous formulation gets EU approval. SK Biopharmaceuticals in-licenses second radiopharmaceutical candidate, which has potential to target clear cell renal cell carcinoma.  </li>
</ul>


Sichuan Kelun-Biotech announces Phase 3 trial success for ADC-Keytruda combination therapy in first-line lung cancer. ImmuneOnco received Phase 3 trial approval for IMM0306 lenalidomide combination for follicular lymphoma in China.
Otsuka received FDA accelerated approval of Voyxact for immunoglobulin A nephropathy. Eisai has completed FDA submission of Leqembi Iqlik subcutaneous autoinjector as a weekly starting dose for early Alzheimer’s disease.
Alteogen secures $15M milestone payment from Merck as Keytruda subcutaneous formulation gets EU approval. SK Biopharmaceuticals in-licenses second radiopharmaceutical candidate, which has potential to target clear cell renal cell carcinoma.  


APAC Healthcare Weekly (November 30) – Kelun Bio, ImmuneOnco, Otsuka, Eisai, Alteogen, SK Biopharma

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>After the centralized procurement in Hebei Province included OK lens, products with high gross margin and low market penetration rate seem to be the new trend of centralized procurement.</li>
<li>Although the current valuation of healthcare industry is relatively low compared with historical levels, that comparison is of little significance due to the fast pace of change.</li>
<li>In terms of when domestic biotech companies could achieve break-even, there is some logic actually. Investors can estimate the time for biotechs to achieve profitability.</li>
</ul>


After the centralized procurement in Hebei Province included OK lens, products with high gross margin and low market penetration rate seem to be the new trend of centralized procurement.
Although the current valuation of healthcare industry is relatively low compared with historical levels, that comparison is of little significance due to the fast pace of change.
In terms of when domestic biotech companies could achieve break-even, there is some logic actually. Investors can estimate the time for biotechs to achieve profitability.


China Healthcare Weekly (Oct28)-OK Lens VBP, Time Required for Biotech to Make Profit, World Changes

Industry viewpoints:
<ul>
<li>The State Council has released a landmark document to define its medical insurance plan for the next four years.</li>
<li>It can be seen that the NHSA has clarified the direction and the coverage of "basic" medical insurance on some high-value consumables such as dental implants.</li>
<li>Related policies are released to support domestic medical devices and consumables. </li>
</ul>
Company news:
News about the updated progress on new drugs and cooperation agreement of <a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH)</a>, <a href="https://www.smartkarma.com/entities/jw-therapeutics" target="_blank" data-smartkarma-citation="entities:29679:1" rel="noopener">JW Therapeutics (2126 HK)</a> and <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>.
Market review: 
Last week, stock price for healthcare sector in A share increased 0.05%, while CSI 300 increased 0.27% over the same period of time. 
Risk disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Industry viewpoints:

The State Council has released a landmark document to define its medical insurance plan for the next four years.
It can be seen that the NHSA has clarified the direction and the coverage of "basic" medical insurance on some high-value consumables such as dental implants.
Related policies are released to support domestic medical devices and consumables. 

Company news:
News about the updated progress on new drugs and cooperation agreement of Jiangsu Hengrui Medicine (600276 CH), JW Therapeutics (2126 HK) and Innovent Biologics Inc (1801 HK).
Market review: 
Last week, stock price for healthcare sector in A share increased 0.05%, while CSI 300 increased 0.27% over the same period of time. 
Risk disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China Healthcare Weekly (Oct.1) - A Landmark Document Released, Dental Implants, Core Data Security

Industry Viewpoints:<ul>
<li>Eight departments jointly issued the pilot plan for deepening the price reform of medical services.</li>
<li>New document was released to regulate the medical beauty advertisement.</li>
<li>With labels such as "whitening", "keeping healthy" and "anti-aging", related functional food has captured the "health anxiety" of young people. </li>
</ul>Company News:News about the updated progress on new drugs of <a href="https://www.smartkarma.com/entities/jw-therapeutics" target="_blank" data-smartkarma-citation="entities:29679:1" rel="noopener">JW Therapeutics (2126 HK)</a>, <a href="https://www.smartkarma.com/entities/innovent-biologics-inc" target="_blank" data-smartkarma-citation="entities:27452:1" rel="noopener">Innovent Biologics Inc (1801 HK)</a>, Gloria Biosciences,<a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene Ltd (6160 HK) </a>and <a href="https://www.smartkarma.com/entities/jacobio-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:29696:1" rel="noopener">Jacobio Pharmaceuticals (1167 HK)</a>. Market Review:Last week, stock price for healthcare sector in A share decreased 2.03%, while CSI 300 increased 0.33% over the same period of time.Risk Disclosure: Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Industry Viewpoints:
Eight departments jointly issued the pilot plan for deepening the price reform of medical services.
New document was released to regulate the medical beauty advertisement.
With labels such as "whitening", "keeping healthy" and "anti-aging", related functional food has captured the "health anxiety" of young people. 
Company News:News about the updated progress on new drugs of JW Therapeutics (2126 HK), Innovent Biologics Inc (1801 HK), Gloria Biosciences,BeiGene Ltd (6160 HK) and Jacobio Pharmaceuticals (1167 HK). Market Review:Last week, stock price for healthcare sector in A share decreased 2.03%, while CSI 300 increased 0.33% over the same period of time.Risk Disclosure: Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

China Healthcare Weekly (Sep.3) - Price Reform of Medical Services, Medical Beauty, Functional Food

China

JW Therapeutics is a clinical-stage cell therapy company focused on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product is Carteyva (relmacabtagene autoleucel), an autologous anti-CD19 CAR-T therapy. The company is headquartered in Shanghai, China, and was founded in 2016.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

JW Therapeutics (2126 HK)

Primer: JW Therapeutics (2126 HK) - Aug 2026

JW Therapeutics is a clinical-stage cell therapy company at the forefront of China's nascent but rapidly growing CAR-T market, with its lead...

αSK Primers

APAC Healthcare Weekly (November 30) – Kelun Bio, ImmuneOnco, Otsuka, Eisai, Alteogen, SK Biopharma

Kelun Bio announces Phase 3 trial success for ADC-Keytruda combo in first-line lung cancer. Otsuka got FDA approval for IgAN drug. Alteogen secures...

Tina Banerjee

China Healthcare Weekly (Oct28)-OK Lens VBP, Time Required for Biotech to Make Profit, World Changes

OK lens VBP means the goal of VBP is changed to ensure people's livelihood; It’s of little significance to compare with history since the world...

Xinyao (Criss) Wang

China Healthcare Weekly (Oct.1) - A Landmark Document Released, Dental Implants, Core Data Security

The insight analyzed a landmark document about medical insurance plan for the next four years,the direction and the coverage of basic medical...

Xinyao (Criss) Wang

China Healthcare Weekly (Sep.3) - Price Reform of Medical Services, Medical Beauty, Functional Food

This article mainly analyzed the pilot plan for the price reform of medical services, new regulation on medical beauty advertisement, functional...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)